Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...

Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...

Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced seven data...

Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...

Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...